Serina Therapeutics (SER) Investor presentation summary

Platform overview and innovation

• POZ platform enables next-generation drug product optimization across multiple modalities, including CNS small molecules, immune-silent delivery, and novel ADC payloads.

• Platform re-engineers known active drugs into differentiated products with improved PK, tolerability, and dosing burden.

• Extensive proprietary chemistry and linker technology supports a 'pipeline in a platform' approach, allowing for broad application.

Lead asset and clinical progress

• SER-252, a POZ-apomorphine conjugate, targets advanced Parkinson's disease and is in a Phase 1b registrational study.

• First patient dosed in February 2026; Cohort 1 dosing completed July 2026, with topline data targeted for 1Q 2027.

• Study design includes randomized, double-blind, placebo-controlled SAD and MAD arms to assess safety, tolerability, PK, and exploratory efficacy.

• Cohort 1 safety/tolerability review and advancement to Cohort 2 are near-term milestones.

Market opportunity and differentiation

• Advanced Parkinson's disease represents a large, underpenetrated market, with ~250K patients inadequately controlled on oral therapy in US/EU4+UK.

• Existing continuous therapies validate demand but have limitations such as pump burden, invasiveness, and local site reactions.

• SER-252 aims to deliver continuous therapy via a compact, on-body device with brief wear time, no visible needle, and no daily pump setup.

• Peak annual sales opportunity estimated at $1.8B base case, with upside to $2.7B if market expands.